<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391426</url>
  </required_header>
  <id_info>
    <org_study_id>29547920.9.0000.0068</org_study_id>
    <nct_id>NCT04391426</nct_id>
  </id_info>
  <brief_title>Analysis of Biliary Microbiota in Hepatobiliopancreatic Diseases Compared to Healthy People [MICROBILIO]</brief_title>
  <official_title>Analysis of Biliary Microbiota in Hepatobiliopancreatic Diseases Compared to Healthy People [MICROBILIO]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The performance of the microbiota is observed in all clinical and pathological stages of
      carcinogenesis, since its development, diagnosis and treatment, including prognosis and
      survival. However, it was found that there is a scarcity of studies on biliary microbiota and
      its relationship with hepatobiliopancreatic diseases. Therefore, further investigation is
      necessary, since reaching the biliary microbiota may suggest ways for studies of biomarkers,
      diagnoses, tests and therapies in hepatobiliopancreatic diseases. For this, bile samples will
      be collected in cases and controls patients to characterize the microbiota and its variations
      according to the disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2020</start_date>
  <completion_date type="Anticipated">December 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composition of the biliary microbiota</measure>
    <time_frame>2 years</time_frame>
    <description>In this study, the investigator's objective will be to characterize the specific composition of the biliary microbiota in patients with hepatobiliopancreatic diseases in comparison with healthy people using 16S ribosomal RNA (rRNA) pyrosequencing methods.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pancreatic Diseases</condition>
  <condition>Microbiota</condition>
  <condition>Early Detection of Cancer</condition>
  <condition>Dysbiosis</condition>
  <condition>Biliary Tract Diseases</condition>
  <arm_group>
    <arm_group_label>Patients who will undergo ERCP (case group)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Living liver transplantation donors (control group)</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Tertiary care adult patients with hepatobiliopancreatic diseases compared to healthy
        people, that are living donors of liver transplant
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Endoscopic retrograde cholangiopancreatography (ERCP) candidates (case group)

          -  Patients over 18 years old complete

          -  Patients previously scheduled for ERCP

          -  Cannulation of the bile duct, via the transpapillary route, with the aid of a
             papillotome with an end kept sterile until contact with the papilla

        Liver transplant living-donor (control group)

          -  Patients over 18 years old up to 55 years

          -  Previously selected patients with scheduled surgery

          -  BMI: 18 kg / m² to 28 kg / m²

          -  Blood typing identical to the recipient

          -  Absence of significant medical, psychiatric problems or previous abdominal surgery

          -  Normal laboratory tests: liver function tests, blood count, coagulogram, pregnancy
             test and serology for hepatitis B, C and HIV

          -  Normal imaging exams: CT of the abdomen and pelvis with liver volume (remaining volume
             - 30-40% of the total liver volume), MRI with cholangioresonance

        Exclusion Criteria:

          -  ERCP candidates (case group)

               -  Use of antibiotics during ERCP or in the last 2 months prior to the procedure

               -  Emergency ERCP

               -  Pregnancy

               -  Uncorrected coagulopathy

        Liver transplant living-donor (control group)

          -  Use of antibiotics in the last 2 months prior to the procedure

          -  Pregnancy

          -  Uncorrected coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alberto Meyer, PhD</last_name>
    <phone>+55(11)2661-3323</phone>
    <email>alberto.meyer@usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Sao Paulo School of Medicine</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Alberto Meyer</last_name>
      <phone>+55(11)2661-3323</phone>
      <email>alberto.meyer@usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Alberto Meyer, MD PhD FACS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Diseases</mesh_term>
    <mesh_term>Biliary Tract Diseases</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT04391426/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT04391426/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

